Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elanco Animal Health Incorporated Common Stock (NY:ELAN)

22.85 +0.70 (+3.16%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elanco Animal Health Incorporated Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Why Elanco (ELAN) Stock Is Trading Up Today
Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia. 
Via StockStory
Topics Artificial Intelligence
Demystifying Elanco Animal Health: Insights From 5 Analyst Reviews
 
Via Benzinga
This Mondelez International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
1 Volatile Stock with Exciting Potential and 2 to Question
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
What Does the Market Think About Elanco Animal Health?
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
What Does the Market Think About Elanco Animal Health?
 
Via Benzinga
3 Profitable Stocks Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
The Analyst Verdict: Elanco Animal Health In The Eyes Of 4 Experts
 
Via Benzinga
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval. 
Via Benzinga
This Truist Financial Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
 
Via Benzinga
3 Unpopular Stocks Facing Headwinds
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
ELAN Q1 Earnings Call: Innovation and Product Launches Drive Outlook Amid Macro Uncertainty
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue... 
Via StockStory
Topics World Trade
2 Momentum Stocks with Impressive Fundamentals and 1 to Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
What's Driving the Market Sentiment Around Elanco Animal Health?
 
Via Benzinga
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
Elanco (ELAN) Stock Trades Up, Here Is Why
Shares of animal health company Elanco (NYSE:ELAN) jumped 21.2% in the afternoon session after the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included... 
Via StockStory
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
Elanco beat Q1 expectations with adjusted EPS of $0.37 and raised its 2025 revenue forecast, citing strong demand and favorable currency trends. 
Via Benzinga
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Is the Market Bullish or Bearish on Elanco Animal Health?
 
Via Benzinga
Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue... 
Via StockStory
Elanco (ELAN) Reports Q1: Everything You Need To Know Ahead Of Earnings
Animal health company Elanco (NYSE:ELAN) will be reporting results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga
ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Volatile Stocks with Questionable Fundamentals
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
3 Profitable Stocks Walking a Fine Line
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
3 Value Stocks in the Doghouse
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Peering Into Elanco Animal Health's Recent Short Interest
 
Via Benzinga
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.